Titan Pharmaceuticals

Last updated

Titan Pharmaceuticals, Inc.
Company type Public
Nasdaq:  TTNP
Industry Pharmaceuticals
Headquarters California
Key people
RevenueIncrease2.svg $1.7 million [2]
Total assets Increase2.svg $8.4 million [2]
Number of employees
14 (Nov 2018)
Website titanpharm.com

Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system ("CNS") disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. [3] In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni - a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group. [2] [4]

Contents

Titan's principal asset is Probuphine, [5] [6] a slow-release implant formulation of buprenorphine [7] for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. [8] It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. [6]

History

The company was founded in 1992 and is headquartered in San Francisco, California.

In August 2022, David Lazar was appointed chairman and CEO. [9] He succeeded Marc Rubin, who had held the position since October 2007. [10]

In 2024, the company entered into a merger agreement and became a wholly-owned subsidiary of BSKE Ltd. [11]

References

  1. ↑ "Titan Strengthens Executive Leadership Team With Appointment Of Chief Commercial Officer". Titan Pharmaceuticals, Inc. 2 October 2018.
  2. 1 2 3 "Titan Pharmaceuticals Reports Third Quarter 2018 Financial Results". Titan Pharmaceuticals, Inc. 14 November 2018.
  3. ↑ "Titan Pharma (TTNP) Prices $9.5M Public Offering".
  4. ↑ "Germany's Merck KGaA taking over Molteni Pharma of Italy - Pharmaceuti". www.thepharmaletter.com.
  5. ↑ "Technology". Titan Pharmaceuticals, Inc.
  6. 1 2 "Annual Reports". Titan Pharmaceuticals, Inc.
  7. ↑ Solof, Barry (2013). The therapist's guide to addiction medicine a handbook for addiction counselors and therapists. New York: Central Recovery Press, LLC. p. 98. ISBN   9781937612443 . Retrieved 21 September 2015.
  8. ↑ "Press Announcements - FDA approves first buprenorphine implant for treatment of opioid dependence". www.fda.gov. Retrieved 26 May 2016.
  9. ↑ Carr, Michelle (16 August 2022). "Titan Pharma names new CEO, expands board". BioTuesdays. Retrieved 10 February 2025.
  10. ↑ "Titan Pharmaceuticals Adds Dr. Marc Rubin to Executive Management Team as President and Chief Executive Officer". BioSpace. 26 September 2007. Retrieved 10 February 2025.
  11. ↑ "Titan Pharmaceuticals Embarks on Strategic Merger and Restructuring - TipRanks.com". TipRanks Financial. Retrieved 12 December 2024.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.